1

Introduction to Quantium Health Outcomes

Joshila Shiba

July 2019

2

01 Introduction to Quantium

02 Introduction to Quantium Health Outcomes

03 South African Medical Device Market

04 Real World Evidence – how do we improve patient outcomes

3

Commercial in confidence Our 16 year history assures best practice in privacy and security

•We have built our business based on privacy by design principles for the past 16 years

•No personal information is ever received or held by Quantium

• All information is de-identified using an irreversible tokenisation process with no ability to re-identify individuals

•We apply a higher test than the Privacy Act

•We are GDPR ready

•We use ‘bank grade’ security to store and process our data

•Comply with 200+ security requirements from NAB, Woolworths and other partners

• All partner data is held in a separate restricted environment

• All access to partner data is limited to essential staff only

• Security environment and processes regularly audited by NAB and other data partners

Privacy Security

Quantium believes in using data for progress, with great care and responsibility, as such please respect the commercial in confidence natureof this presentation

We all have a responsibility to use data for good –to power breakthrough possibilities for individuals, organisations and society

4

Introduction to Quantium

01

5

Actuaries

Statisticians

Data Scientists

Product Leaders

Strategy Consultants

Software Engineers

Delivery Managers

Industry Experts

Designers

Futurists

A diverse team:

Hyderabad

Johannesburg

San Francisco

Founded in 2002 in Australia, we have a global team with a unique blend of analytics capabilities

Auckland

Brisbane

Sydney (HQ)

Melbourne

750+Quantium people

9 Offices worldwide, headquartered in Sydney

Bentonville

London

6

Our history

Quantium opens for business

Data partnership

Data partnership and transaction

Media partnership

Mediapartnership

Datapartnership

Mediapartnership

Mediapartnership

Health joint venture

Media partnerships

OC

T 2

00

2

AP

R 2

00

9

MA

Y 2

01

3

MA

Y 2

01

4

AP

R 2

01

5

MA

R 2

01

6

OC

T 2

01

6

OC

T 2

01

7

JU

L 2

01

5

MA

R 2

01

5

MA

R 2

01

4

DE

C 2

01

7

Banking Partnership

7

We work with iconic brands in over 20 countries, partnering on their greatest challenges and unlocking transformational opportunities through:

Government & HealthTop 5 MediaTop 10 Insurers 7 of top 10 Retailers Top 15 CPG Top 10 PropertyTop 5 Banks

Telco Industrial Sport & Culture Airline/Gambling TechnologyCharity Gaming

8

We bring expertise in two core domains to develop cutting-edge solutions for a ‘big data world’

Data Science

We translate raw data into actionable insight

Data cleansing and curation

Data ecosystem

Data monetisation

Applied analytics

Artificial Intelligence

We build transformative data-powered solutions

Decision support tools

Decision engines

Machine learning

9

10

A word from one of our clients

At Walmart, we are always looking at ways to accelerate innovation for the benefit of our customers.

Quantium has developed a world-class data science and AI solution that has transformed the accuracy of Walmart’s prediction of customers’ needs at scale. The solution determines what our customers need, when and where they need it, significantly reducing both stock-outs and wastage.

Quantium’s people combine technical excellence with incisive commerciality. They took the time to really understand Walmart and delivered a solution that has yielded an immediate improvement in customer experience, along with financial benefits at both the cost and revenue lines.

Greg ForanPresident and CEO, Walmart US

11

02

Introduction to Quantium Health Outcomes

12

Quantium Health Outcomes combines data and analytics with medical expertise

Industrial strength analyticsLargest data analytics company in Australia

New innovative productsProven ability to create new innovative products in the industries it works in

Technology platformTop 3 data processing capacity outside of government in Australia

Data ecosystemAbility to combine data from multiple organisations in a privacy compliant way. Ability to integrate publicly available data from ABS or AEC

Quantium Health Outcomes is a joint venture that combines the analytical IP and data assets of Quantium, the health and wellnessIP within Discovery, and the clinical expertise and implementation of Health Outcomes Australia

Recognised global leader in utilising health dataLargest health insurer in South Africa. Bespoke health classifications and tools including patient complexity tools, clinical and economic health technology evaluation and proprietary data assets

Deployment of health tools and assetsExtensive experience in deploying health data tools and assets in value based procurement, disease management and clinical policy development

Health data 5 million lives including health, life insurance and lifestyle data

Woolworths10m loyalty cardholders, trillions of items purchased

NAB2.5m customers, over 4 billion transactions

Foxtel2.8m households, every click on the remote control since January 2014

Media partnerships with Facebook, Google, News Corp, Woolworths and oOh! Media

Access to the data from Quantium’s data partners

Quantium PartnersCapability in health

Quantium Health Outcomes

Recognised leader in supporting clinicians and patients to measure and understand health outcomesHOA work with clinicians and patients, with government and corporations to collect health outcomes data, understand its implications and act to lead positive change

Experienced leaders in clinical integrationExtensive experience in working with health providers to integrate new findings into best practice

13

2bn Data

records

40% Private Market

10 YrsLongitudinal

data

3.6m Insured lives

Quantium Health Outcomes has developed the most comprehensive Global Medical Device Nomenclature Database (GMDN) in South Africa . Currently over 50

000 medical device products are mapped to a GMDN code. GMDN provides for a first time , an international standard for identifying all medical

devices at a generic level in a meaningful manner that can be understood by all users.

Vitality Wellness

Data

14

03

South African Medical Device Market

15

South African Medical Device Market 2018

R12bnTotal Spend

3% YoY Growth overall

1017# Competitors

#ProductCategories

168

16

Web based self service insight portal for the medical device market. Provide access to market insights across product portfolios.Helps businesses drive strategies across products,regions,providers and treatment areas. Q.Checkup provides a 360 view of your market performance to help you understand how best to grow your business

Product Overview Product Snapshot

Breakdown by product category, provider, location and medical condition

Allows the creation of specific sales forces data and monitoring performance

Providing 5 years sales and market share trends

Data is up to date and refreshed monthly

9

34

55

0 10 20 30 40 50 60

DILATATION CATHETERS/BALLOONS

WOUND MANAGEMENT

STENTS AND GRAFTS

Number of new nappi codes

New Product Launches

New Market Reports – Gain insight into the market performance of specific product categories to understand market potential and price points, allowing for strategically planned market entry

17

18

Representation and use cases

ResultsClients have generated tangible benefits: e.g. targeted remediation of market losses, market entry no-go’s, strengthened funder negotiations

RepresentationOur clients represent R7.5bn of annual total private market spend

Clients25 of the largest suppliers make use of our tools and analytical consulting services

19

Our services have been used across several disease areas in South Africa

20

Our data enables businesses to drive success

In the medical space in SA it was always hard to reallyjudge where we stand in terms of market share andperformance of our business and products in the market.All our estimates would be based on guesses and with noreal informed data. Your platform and data provide uswith eye opening information on where to take ourbusiness. Not only has the information changed the waywe approach our product segmentation but also a totalnew approach to our business.

Nico CoetzeeCEO, Essilor South Africa

To date the marketing environment in our industry had nodata to support our assumptions. We could only build ourmarketing models based on knowledge gained from thefield. The Quantium toolkit provides us with immediateaccess to our business and market share information.This assists us with our sales management to monitorthe performance in each region.

Q.CheckUp userNational Sales and Marketing Manager

In a market where we historically had to make a lot ofassumptions it is of tremendous help to now have anopportunity to check and confirm assumptions made.This tool assists me to optimise my resources and planon future growth strategies and have more realisticgrowth expectations not just per product but also perterritory.

Q.CheckUp userBusiness Unit Director

QHO is one of the few companies that take the time tolisten to your concerns surrounding the outcomes oftheir analysis. They are willing to look at the datadifferently to answer all questions. Open communication,knowledge sharing and adaptability are key attributesfrom the analytics team and part of their success.

Charmaine Timm-MilliganHead: Strategic Planning & Business Development

Roche Products

21

04

Real world evidence – how do we improve patient outcomes

22

Example 1: Health Outcomes Measures

Retrospective study of patients receiving PCI with different Drug Eluting Stents

1. Compare clinical outcomes - Major adverse cardiac events

2. Compare downstream cost implications

Using real-world data, determine the downstream costs of complications associated with each option

Aggregate initial and downstream costs to demonstrate superior long-term economical outcomes

Application in medical devices- Drug Eluting Stents

Drug No-MACE MACE Total Percentage

DES Stent 1 2058 193 2251 8.6%

DES Stent 2 2333 196 2529 7.8%

DES Stent 3 1867 149 2016 7.4%

Grand Total 2781 4015 6796 7.9%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0-1

9

40

-59

10

0-1

19

14

0-1

59

18

0-1

99

22

0-2

39

28

0-2

99

32

0-3

39

36

0-3

79

40

0-4

19

46

0-4

79

50

0-5

19

56

0-5

79

62

0-6

39

70

0-7

19

74

0-7

59

78

0-7

99

10

20

-10

39

Per

cen

tage

of

Dea

ths

Number of days post-procedure

Stent A Stent B Stent C

23

Example 2: Measuring clinical outcomes of comparable treatments

Motivate for the use of safer catheterisation products in specific populations

Using real-world data, determine the infection rates in patients using each device type

Demonstrate differences in rates of infection between the treatment options available

Use results to educate providers and patients in their choice of catheterisation products

Application in treatment risks

0%

2%

4%

6%

0 1 2 3 4 5 6 7 8 9 10 11

UT

I p

ati

en

ts

Months since catheterisation commenement

Percentage of patients developing UTIs

Single-use catheters Reusable catheters

24

Example 3: Measuring downstream costs of comparable devices

Motivate for the necessity of enhanced material in implantable ocular device

Using real-world data, determine the downstream costs of complications associated with each option

Aggregate initial and downstream costs to demonstrate superior long-term economical outcomes

Use results to educate providers and inform payer discussions

Application in medical devices

0

500

1 000

1 500

2 000

0 12 24 36 48

Co

st

pe

r e

ye (

R)

Months since device implant

Cummulative downstream costs of complication A per eye

Client's enhanced product Competitors' enhanced products Competitors' standard products

-

10 000

20 000

30 000

40 000

Alcon- Hydrophobic Competitor- Hydrophilic Competitor- Hydrophobic

Ave

rag

e c

os

t (R

)

Total 48-month cost outcomes by product

Device Complication A Complication B Complication C Consultation Medication

Client

25

Disclaimer: This report comprises, and is the subject of intellectual property (including copyright) and confidentiality rights of one or multiple owners, including The Quantium Group Pty Limited (Quantium) and where applicable,its third-party data owners (Data Providers), together (IP Owners). The information contained in this report may have been prepared using raw data owned by the Data Providers. The Data Providers have not been involved in theanalysis of the raw data, the preparation of, or the information contained in the report. The IP Owners do not make any representation (express or implied), nor give any guarantee or warranty in relation to the accuracy,completeness or appropriateness of the raw data, nor the analysis contained in this report. None of the IP Owners will have any liability for any use or disclosure by the recipient of any information contained in, or derived fromthis report. To the maximum extent permitted by law, the IP Owners expressly disclaim, take no responsibility for and have no liability for the preparation, contents, accuracy or completeness of this report, nor the analysis onwhich it is based. This report is provided in confidence, may only be used for the purpose provided, and may not be copied, reproduced, distributed, disclosed or made available to a third party in any away except strictly inaccordance with the applicable written terms and conditions between you and Quantium, or otherwise with Quantium’s prior written permission.

Thank you